In addition to the solid role of SGLT2-i as a first-line therapy for DM, CKD, and CHF, gliflozins also contribute to slowing the progression of atherosclerosis and its vascular complications by modulating the inflammatory process. Here, SLC5A2 is linked to diabetes mellitus.